论文部分内容阅读
为了评价特比萘芬(torbinafine,商品名疗霉舒)短程间隔疗法治疗甲真菌病的疗效和不良反应,瑞士山德士(Sandoz)药厂从1994年1～12月组织部分医院进行多中心临床验证。一、病例与方法1.病例选择:门诊的甲真菌病患者,经临床及真菌学证实,征得患者同意且愿意合作者,可入选。育龄妇女需有合适避孕措施。凡有下列情况者不入选:①3个月内用过系统性抗真菌药,1个月内用过局部抗真菌剂者;②治疗前2周或近期内接受过放疗,系统性免疫抑
In order to evaluate the efficacy and adverse effects of short-interval therapy with terbinafine for treatment of onychomycosis, the Swiss Sandoz Pharmaceutical Factory organized a multi-center hospital from January to December 1994 Clinical validation. First, the cases and methods 1. Case Selection: Outpatient onychomycosis patients, confirmed by clinical and mycological, patient consent and willing to cooperate, may be selected. Women of childbearing age need appropriate contraception. Where the following conditions are not selected: ① 3 months had used systemic antifungal drugs, used within 1 month of topical antifungal agents; ② 2 weeks before or within the recent treatment received radiotherapy, systemic immunosuppression